Welcome to our dedicated page for Gabelli Health & Wellness SEC filings (Ticker: GRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
From oncology breakthroughs to plant-based nutrition, Gabelli Healthcare & WellnessRx Trust (GRX) discloses how it positions capital inside the fast-moving health and wellness universe. Whether you are comparing portfolio turnover or checking how much of the fund is allocated to medical devices versus pharmaceuticals, the details live inside GRX’s SEC docket—now decoded for you on Stock Titan.
Our platform gathers every form—annual report (N-CSR or the familiar 10-K), quarterly holdings (10-Q or N-PORT), 8-K material event notices, proxy statements on executive compensation, and the Form 4 insider trading filings—all in one feed with real-time EDGAR updates. AI-powered summaries translate dense language into plain English, so “Gabelli Healthcare & WellnessRx Trust SEC filings explained simply” is more than a promise—it is a click away. You will also find natural language answers to searches like “Gabelli Healthcare & WellnessRx Trust insider trading Form 4 transactions” or “understanding Gabelli Healthcare & WellnessRx Trust SEC documents with AI.”
Investors use these disclosures to track discount-control plans, monitor “Gabelli Healthcare & WellnessRx Trust executive stock transactions Form 4,” and study segment weightings before earnings season. Want the next “Gabelli Healthcare & WellnessRx Trust quarterly earnings report 10-Q filing” or an alert when management files an 8-K? Our AI flags the numbers that drive dividend sustainability and highlights risk factors without the jargon. Explore:
- “Gabelli Healthcare & WellnessRx Trust annual report 10-K simplified” for sector allocation trends
- “Gabelli Healthcare & WellnessRx Trust 8-K material events explained” to gauge portfolio shifts
- “Gabelli Healthcare & WellnessRx Trust proxy statement executive compensation” for governance insights
- “Gabelli Healthcare & WellnessRx Trust earnings report filing analysis” with instant AI commentary
- “Gabelli Healthcare & WellnessRx Trust Form 4 insider transactions real-time” to track manager buys and sells
Complex filings, clear answers—delivered by Stock Titan’s AI in seconds.
Schedule 13D/A Amendment No. 6 for Gabelli Healthcare & Wellness Rx Trust (GRX) Preferred Shares discloses updated ownership information for multiple Gabelli-related entities and individuals.
Aggregate ownership: The Reporting Persons now hold 1,514,000 preferred shares, equal to 45.49 % of the 3,328,500 shares outstanding as of 30 Jun 2025. Key positions include:
- Associated Capital Group (AC): 400,000 shares – 12.02 %
- GAMCO Investors (GBL): 400,000 shares – 12.02 %
- Mario J. Gabelli (individual): 400,000 shares – 12.02 %
- Gabelli Foundation: 314,000 shares – 9.43 %
Recent transactions (26 Jun 2025): Several entities surrendered a total of 1,440,000 preferred shares (Series E & Series G) at $10.00 per share under the Fund’s put right to redeem up to 100 % of its outstanding cumulative preferred stock. The largest single surrender was 830,000 shares by Mario J. Gabelli.
Post-transaction, the group retains a controlling minority of the preferred class, maintaining significant influence over matters requiring preferred-shareholder approval. All reporting persons exercise sole voting and dispositive power over their respective holdings; no shared power is reported. No new legal proceedings or changes in control arrangements were disclosed.
Implications for investors: While the surrender materially reduces absolute ownership, the group’s collective stake remains large at 45 %. The buy-back at par ($10) may signal limited upside in the current preferred valuation and could affect liquidity of the remaining float. However, continued alignment of interests between the Gabelli entities and preferred shareholders persists.
Medicus Pharma Ltd. (Nasdaq: MDCX) filed Prospectus Supplement No. 3 to update investors on a third and final draw under its May 2, 2025 Securities Purchase Agreement with YA II PN, Ltd. (Yorkville). On June 17, 2025 Yorkville purchased a $2.5 million debenture, bringing aggregate principal issued to the maximum $5 million. Net cash proceeds total $4.5 million after original-issue discounts. Each debenture carries 8.0 % annual interest, rising to 18 % upon default, and matures on February 2, 2026. The notes are guaranteed by all subsidiaries via a global guaranty. Medicus remains an emerging-growth company and warns prospective investors to review Risk Factors in the base prospectus. This filing does not add new securities, but refreshes disclosure and incorporates the June 20, 2025 Current Report detailing the new debt obligation.
C4 Therapeutics, Inc. (NASDAQ: CCCC) filed an 8-K to disclose the results of its 18 June 2025 Annual Meeting and a charter amendment. Stockholders approved doubling the Company’s authorized common shares to 300 million, effective upon the same-day filing of a Certificate of Amendment with the Delaware Secretary of State. This change provides the Board added flexibility for future equity-based financing, M&A currency, and incentive plans, but also increases potential dilution for existing holders.
All three Class II directors—Ronald Harold Wilfred Cooper, Donna Grogan, M.D., and Steven Hoerter—were re-elected for terms expiring at the 2028 annual meeting. Vote support ranged from 79.0 % to 99.6 % of shares cast, with sizeable broker non-votes (10.5 million shares).
Shareholders delivered strong (≈97.6 %) advisory approval of named executive officer (NEO) compensation. KPMG LLP was ratified as independent auditor for fiscal 2025 with 99.7 % support. The share-increase proposal passed with 65.7 % “For” (39.5 million vs 20.7 million “Against”), indicating some concern among holders about dilution. No other matters were presented, and no financial results were reported.
FAQ
What is the current stock price of Gabelli Health & Wellness (GRX)?
What is the market cap of Gabelli Health & Wellness (GRX)?
What type of investment company is Gabelli Health & Wellness?
Which sectors does the company primarily invest in?
How does Gabelli Health & Wellness generate its revenue?
What distinguishes Gabelli Health & Wellness from other investment funds?
What is the company's investment strategy?
How does the company manage risk within its investment portfolio?
What kind of investor is Gabelli Health & Wellness suited for?
How does Gabelli Health & Wellness differentiate itself in the competitive financial services market?
